keyword
MENU ▼
Read by QxMD icon Read
search

Endometrioid

keyword
https://www.readbyqxmd.com/read/29456726/association-of-histone-deacetylase-expression-with-histology-and-prognosis-of-ovarian-cancer
#1
Mitsutake Yano, Masanori Yasuda, Mika Sakaki, Koji Nagata, Takashi Fujino, Eiichi Arai, Takahiro Hasebe, Masaki Miyazawa, Mariko Miyazawa, Naoki Ogane, Kosei Hasegawa, Hisashi Narahara
Histone deacetylase (HDAC) inhibitor is known to have a cytotoxic effect on ovarian cancer cell lines. The present study analyzed the association between immunohistochemical HDAC expression and clinicopathological findings, in particular, the association with histological type and effect of chemotherapy. The histology of the 201 ovarian cancers addressed was as follows: Serous carcinoma (SEC), 100 cases; clear cell carcinoma (CCC), 56 cases; endometrioid carcinoma (EMC), 36 cases; and mucinous carcinoma (MUC), 9 cases...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29451900/the-arid1a-p53-and-%C3%A3-catenin-statuses-are-strong-prognosticators-in-clear-cell-and-endometrioid-carcinoma-of-the-ovary-and-the-endometrium
#2
Marlene Heckl, Elisa Schmoeckel, Linda Hertlein, Miriam Rottmann, Udo Jeschke, Doris Mayr
AIM: The objective of this study was to evaluate the prognostic value of ARID1A, p53, p21, p16 and ß-Catenin in endometrioid and clear cell ovarian and endometrial carcinomas. MATERIALS AND METHODS: 97 tumors were available for analysis of ARID1A, p53, p21, p16 and ß-Catenin with the techniques of tissue microarray and immunohistochemistry. 32 were ovarian carcinomas and 65 were endometrial carcinomas. RESULTS: Endometrioid ovarian carcinomas showed negative staining for ARID1A (a) and p21 (b), aberrant expression of p53 (c) and p16 (d) and ß-Catenin positive nuclear expression (e) respectively in 19% (a), 100% (b), 28...
2018: PloS One
https://www.readbyqxmd.com/read/29449346/shikonin-suppresses-proliferation-and-induces-apoptosis-in-endometrioid-endometrial-cancer-cells-via-modulating-mir-106b-pten-akt-mtor-signaling-pathway
#3
Caimei Huang, Guohua Hu
Shikonin, a natural naphthoquinone isolated from a traditional Chinese medicinal herb, which exerts anti-cancer effects in various cancers. However, the molecular mechanisms underlying the therapeutic effects of shikonin against endometrioid endometrial cancer (EEC) have not yet been fully elucidated. Herein, we investigated anti-cancer effects of shikonin on EEC cells and explored the underlying molecular mechanism. We observed that shikonin inhibits proliferation in human EEC cell lines with in a dose-dependent manner...
February 15, 2018: Bioscience Reports
https://www.readbyqxmd.com/read/29449189/adjuvant-chemoradiotherapy-versus-radiotherapy-alone-for-women-with-high-risk-endometrial-cancer-portec-3-final-results-of-an-international-open-label-multicentre-randomised-phase-3-trial
#4
Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Ina M Jürgenliemk-Schulz, Henry C Kitchener, Hans W Nijman, Godfrey Wilson, Susan Brooks, Silvestro Carinelli, Diane Provencher, Chantal Hanzen, Ludy C H W Lutgens, Vincent T H B M Smit, Naveena Singh, Viet Do, Romerai D'Amico, Remi A Nout, Amanda Feeney, Karen W Verhoeven-Adema, Hein Putter, Carien L Creutzberg
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup...
February 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29449000/an-immunohistochemical-and-molecular-analysis-of-papillary-proliferation-of-the-endometrium
#5
Colin J R Stewart, Susan Bigby, Tino Giardina, Fabienne Grieu-Iacopetta, Benhur Amanuel
Papillary proliferations of the endometrium (PPEs) are uncommon lesions that are often associated with endometrial polyps. PPEs occasionally precede or co-exist with atypical endometrial hyperplasia or adenocarcinoma, but their pathogenesis and relationship to endometrial neoplasia is uncertain. In the present study 11 PPEs, including eight benign papillary proliferations (BPPs) and three complex papillary hyperplasias (CPHs) were examined immunohistochemically for expression of PAX2, BAF250a, p16, β-catenin and DNA mismatch repair (MMR) proteins...
February 12, 2018: Pathology
https://www.readbyqxmd.com/read/29442399/clinicopathologic-characteristics-of-double-primary-endometrial-and-colorectal-cancers-in-a-single-institution
#6
Hyun J Lee, Min C Choi, Ja-Hyun Jang, Sang G Jung, Hyun Park, Won D Joo, Tae H Kim, Chan Lee, Je H Lee
AIM: To investigate the clinicopathologic and genetic correlations between double primary endometrial and colorectal cancer related to Lynch syndrome and to analyze germline mutations in mismatch repair genes in endometrial cancer patients in Korea. METHODS: Thirteen patients diagnosed with pathologically endometrial and colorectal cancer between January 2005 and November 2016 in a single institution were enrolled in the study. The medical records were retrospectively analyzed...
February 14, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29440294/in-vitro-and-in-vivo-activity-of-imgn853-an-antibody-drug-conjugate-targeting-folate-receptor-alpha-linked-to-dm4-in-biologically-aggressive-endometrial-cancers
#7
Gary Altwerger, Elena Bonazzoli, Stefania Bellone, Tomomi Egawa-Takata, Gulden Menderes, Francesca Pettinella, Anna Bianchi, Francesco Riccio, Jacqueline Feinberg, Luca Zammataro, Chanhee Han, Ghanshyam Yadav, Katherine Dugan, Ashley Morneault, Jose F Ponte, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Gloria S Huang, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose of this study was to determine folic acid receptor alpha (FR⍺) expression in these biologically aggressive (Type II) endometrial cancers,and evaluate FR⍺ as a targetable receptor for IMGN853 (Mirvetuximab soravtansine). The expression of FR⍺ was evaluated by immunohistochemistry (IHC) and flow cytometry in 90 endometrioid and USC samples. The in vitro cytotoxic activity and bystander effect were studied in primary uterine cancer cell lines expressing differential levels of FR⍺...
February 13, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29433406/chest-wall-metastasis-of-endometrial-cancer-case-report-and-review-of-the-literature
#8
Osman Nuri Dilek, Emine Özlem Gür, Turan Acar, Serpil Aydoğmuş
INTRODUCTION: Endometrial cancer is the fourth most common female cancer and also distant metastases to the chest wall associated with these tumors are seen less common. Surgical treatment options for metastases of endometrial cancer are limited. CASE: A 57-year-old patient who underwent total abdominal hysterectomy + bilateral salpingo oophorectomy and received adjuvant chemotherapy for endometrioid-type adenocarcinoma of the endometrium and tuba is presented...
February 12, 2018: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/29432521/final-validation-of-the-promise-molecular-classifier-for-endometrial-carcinoma-in-a-large-population-based-case-series
#9
S Kommoss, M K McConechy, F Kommoss, S Leung, A Bunz, J Magrill, H Britton, F Kommoss, F Grevenkamp, A Karnezis, W Yang, A Lum, B Krämer, F Taran, A Staebler, S Lax, S Y Brucker, D G Huntsman, C B Gilks, J N McAlpine, A Talhouk
Introduction: Based on The Cancer Genome Atlas, we previously developed and confirmed a pragmatic molecular classifier for endometrial cancers; ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). ProMisE identifies four prognostically distinct molecular subtypes, and can be applied to diagnostic specimens (biopsy/curettings), enabling earlier informed decision-making. We have strictly adhered to the Institute of Medicine (IOM) guidelines for the development of genomic biomarkers, and herein present the final validation step of a locked-down classifier prior to clinical application...
February 7, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29426745/single-institutional-outcomes-of-adjuvant-brachytherapy-for-stage-i-endometrial-cancer-are-outcomes-consistent-with-randomized-studies
#10
Michael J Dohopolski, Zachary D Horne, Brian J Gebhardt, Scott M Glaser, Robert P Edwards, Joseph L Kelley, John T Comerci, Alexander B Olawaiye, Madeleine Courtney-Brooks, Jessica L Berger, Paniti Sukumvanich, Sushil Beriwal
PURPOSE: Vaginal brachytherapy (VBT) alone has been shown to be a viable adjuvant treatment strategy for most patients with Stage I endometrioid endometrial cancer. We sought to examine our institutional data following practice pattern changes resulting from the publications of GOG-99 and PORTEC-2. METHODS AND MATERIALS: We retrospectively analyzed women who underwent adjuvant VBT after surgical staging for Stage 1 endometrioid endometrial cancer at our institution from 2007 to 2014...
February 6, 2018: Brachytherapy
https://www.readbyqxmd.com/read/29423077/integrating-the-dysregulated-inflammasome-based-molecular-functionome-in-the-malignant-transformation-of-endometriosis-associated-ovarian-carcinoma
#11
Chia-Ming Chang, Mong-Lien Wang, Kai-Hsi Lu, Yi-Ping Yang, Chi-Mou Juang, Peng-Hui Wang, Ren-Jun Hsu, Mu-Hsien Yu, Cheng-Chang Chang
The coexistence of endometriosis (ES) with ovarian clear cell carcinoma (CCC) or endometrioid carcinoma (EC) suggested that malignant transformation of ES leads to endometriosis associated ovarian carcinoma (EAOC). However, there is still lack of an integrating data analysis of the accumulated experimental data to provide the evidence supporting the hypothesis of EAOC transformation. Herein we used a function-based analytic model with the publicly available microarray datasets to investigate the expression profiling between ES, CCC, and EC...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29418038/imaging-in-gynecological-disease-clinical-and-ultrasound-characteristics-of-endometrioid-ovarian-cancer
#12
F Moro, G Magoga, T Pasciuto, F Mascilini, M C Moruzzi, D Fischerova, L Savelli, S Giunchi, R Mancari, D Franchi, A Czekierdowski, W Froyman, D Verri, E Epstein, V Chiappa, S Guerriero, G F Zannoni, D Timmerman, G Scambia, L Valentin, A C Testa
OBJECTIVE: To describe the clinical and ultrasound characteristics of ovarian pure endometrioid carcinoma. METHODS: This is a retrospective multicenter study. From the International Ovarian Tumor Analysis (IOTA) database we identified 161 patients with a histological diagnosis of pure endometrioid carcinoma, who had undergone preoperative ultrasound examination by an experienced ultrasound examiner between 1999 and 2016. Another 78 patients with a histological diagnosis of pure endometrioid carcinoma were identified from the databases of the departments of gynecological oncology in the participating centers...
February 8, 2018: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29416878/genomic-profiling-identifies-gpc5-amplification-in-association-with-sarcomatous-transformation-in-a-subset-of-uterine-carcinosarcomas
#13
M Herman Chui, Cherry Have, Lien N Hoang, Patricia Shaw, Cheng-Han Lee, Blaise A Clarke
Uterine carcinosarcoma, also known as Malignant Mixed Müllerian Tumour, is a high-grade biphasic neoplasm composed of sarcomatous elements thought to originate via transdifferentiation from high-grade endometrial carcinoma. To identify molecular factors contributing to the histogenesis of this tumour, we analyzed DNA extracted from matched carcinoma and sarcoma components from 12 cases of carcinosarcoma by a molecular inversion probe microarray to assess genomic copy number alterations (CNAs) and allelic imbalances...
January 2018: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/29416671/prostaglandin-receptor-ep3-regulates-cell-proliferation-and-migration-with-impact-on-survival-of-endometrial-cancer-patients
#14
Junyan Zhu, Fabian Trillsch, Doris Mayr, Christina Kuhn, Martina Rahmeh, Simone Hofmann, Marianne Vogel, Sven Mahner, Udo Jeschke, Viktoria von Schönfeldt
Background: Prostaglandin E2 (PGE2) receptor 3 (EP3) regulates tumor cell proliferation, migration, and invasion in numerous cancers. The role of EP3 as a prognostic biomarker in endometrial cancer remains unclear. The primary aim of this study was to analyze the prognostic significance of EP3 expression in endometrial cancer. Methods: We analyzed the EP3 expression of 140 endometrial carcinoma patients by immunohistochemistry. RL95-2 endometrial cancer cell line was chosen from four endometrial cancer cell lines (RL95-2, Ishikawa, HEC-1-A, and HEC-1-B) according to EP3 expression level...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29410139/significance-of-microcystic-elongated-and-fragmented-glandular-like-features-in-intraductal-papillary-mucinous-neoplasm-of-the-pancreas
#15
Ji Y Park, Jae Hoon Lee, Ki-Byung Song, Dae Wook Hwang, Kyu-Rae Kim, Song Cheol Kim, Seung-Mo Hong
Microcystic, elongated, and fragmented (MELF) glandular features are associated with epithelial-mesenchymal transition, invasion, and progression in endometrioid adenocarcinoma of the uterus. Similar histological features are also observed at the periphery of pancreatic intraductal papillary mucinous neoplasms (IPMNs). However, the clinicopathological significance of MELF-like features-particularly whether they represent regenerative or truly neoplastic conditions-in IPMNs remains unclear. We assessed a total of 152 surgically resected IPMNs...
February 1, 2018: Human Pathology
https://www.readbyqxmd.com/read/29408747/risk-factors-for-ovarian-involvement-in-young-and-premenopausal-endometrioid-endometrial-cancer-patients
#16
Jun Li, Qin Zhu, Bingyi Yang, Chengcheng Ning, Xiaoxia Liu, Xuezhen Luo, Xiaojun Chen
OBJECTIVE: This study aimed to investigate the incidence of ovarian malignant involvement in young and premenopausal endometrioid endometrial cancer and study the possible risk factors. METHODS: Premenopausal patients 45 years of age or younger with endometrioid endometrial cancer treated at the OB/GYN Hospital of Fudan University between 2009 and 2013 were identified. The incidence of ovarian malignant involvement in young and premenopausal endometrioid endometrial cancer patients were calculated and the possible risk factors were investigated...
January 31, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29406333/a-case-report-of-an-adenomatoid-tumor-of-the-uterus-mimicking-an-endometrioid-adenocarcinoma-on-endometrial-curetting-a-diagnostic-pitfall
#17
Paulette Mhawech-Fauceglia, Damanzoopinder Samroa
Adenomatoid tumors (AT) arising in the female genital tract are usually incidental findings occurring most often in the fallopian tube and uterine serosa and rarely in the myometrium. In the myometrium, they appear grossly as deep seated, small, firm, ill circumscribed nodules mimicking leiomyoma. Histologically they show a glandular and invasive pattern making well-differentiated/low-grade endometrioid adenocarcinoma a major differential diagnosis. However, this differential is rarely encountered in practice because myometrial AT is usually seen on the hysterectomy specimen, because of their anatomic position in the deep myometrium, and only rarely in endometrial curettings...
February 5, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/29400419/endometrioid-carcinoma-arising-from-diaphragmatic-endometriosis-treated-with-laparoscopy-a-case-report
#18
Hiroyuki Okimura, Hiroshi Tatsumi, Fumitake Ito, Suguru Yamashita, Tetsuya Kokabu, Jo Kitawaki
Malignant transformation of diaphragmatic endometriosis is rare. We present a case of endometrioid carcinoma arising from diaphragmatic endometriosis treated with laparoscopy. A 59-year-old primigravida woman who had undergone abdominal hysterectomy for adenomyosis at the age of 47 years was referred to our hospital for investigation of a tumor on the surface of the liver. An integrated positron emission tomography-computed tomography scan revealed a 3-cm nodule on the surface of the liver with abnormal fluorine-18-deoxyglucose accumulation...
February 5, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29400014/is-repeated-high-dose-medroxyprogesterone-acetate-mpa-therapy-permissible-for-patients-with-early-stage-endometrial-cancer-or-atypical-endometrial-hyperplasia-who-desire-preserving-fertility
#19
Wataru Yamagami, Nobuyuki Susumu, Takeshi Makabe, Kensuke Sakai, Hiroyuki Nomura, Fumio Kataoka, Akira Hirasawa, Kouji Banno, Daisuke Aoki
OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking. We aimed to clarify the outcomes of repeated MPA therapy in cases of intrauterine recurrence after fertility-preserving therapy with MPA against AEH/early G1. METHODS: Patients with AEH or stage IA well-differentiated endometrioid carcinoma without myometrial invasion who underwent first-line MPA therapy for primary lesions or intrauterine recurrence were divided into initial treatment and repeated treatment groups (162 and 82 patients, respectively)...
January 2, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29400013/seromucinous-component-in-endometrioid-endometrial-carcinoma-as-a-histological-predictor-of-prognosis
#20
Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroaki Soyama, Tomoyuki Yoshikawa, Hitoshi Tsuda, Kenichi Furuya
OBJECTIVE: In 2014 World Health Organization criteria, seromucinous carcinoma was defined as a new histological subtype in ovarian carcinomas, but "seromucinous carcinoma" was not defined in endometrial carcinomas. The aim of this study was to identify seromucinous carcinoma resembling ovarian seromucinous carcinoma in endometrial carcinomas, and to evaluate the clinical significance for prognoses of the patients. METHODS: Central pathological review was conducted for patients with endometrioid carcinoma of the endometrium treated by primary surgery at our hospital between 1990 and 2013...
December 22, 2017: Journal of Gynecologic Oncology
keyword
keyword
80266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"